In summary, our results indicate that the expression status of NS, abundant in stem cells, is a prognostic indicator in breast cancer patients, especially for those with luminal-type or HER2-type tumors, and that the coexpression of NS and p53 correlates with poorer prognostic outcomes. This evidence concerns the gene ERBB2 and breast carcinoma.